Clinical Trials
Update: Gene therapy clinical trials in neovascular age-related macular degeneration
Companies are attacking the disease from multiple angles.
Hitting the century mark: 100 candidates and counting
Geographic atrophy continues to be the fastest-growing area of interest, and new entries double the number of dropouts.
A potential gene therapy to treat Stargardt
Phase II results identify patients with macular degeneration phenotype may benefit most from the investigative transgene therapy.
Transgene shows restorative properties in nAMD
4D-150 is an intravitreal dual transgene genetic medicine that expresses both aflibercept and an mRNAi sequence that inhibits intracellular expression of VEGF-C.
Potential of low-light therapy for dry AMD
Trial shows effectiveness of the Valeda Light Delivery System photobiomodulation platform.
Reviving dormant photoreceptors in LCA1
The gene therapy ATSN-101 has demonstrated safety and shown signals of efficacy in restoring vision in Leber congenital amaurosis.
A pill to head off worsening of DRSS
A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.
The potential impact of pegcetacoplan
Clinical implications of data from the OAKS and DERBY trials on the future treatment of geographic atrophy.
2023: The year of geographic atrophy
A comprehensive look at 87 clinical programs for investigative treatments in retina.
Two tales of DR progression
Clinical trials show encouraging outcomes for treating diabetic retinopathy progression, but the real-world evidence tells a different story.
Current Issue
Continuing Medical Education
Additional Publications
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Sponsored by Regeneron
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
Eyepoint Yutiq: A Discussion Among Experts on the Treatment of Uveitis Affecting the Posterior Segment
